Cantargia AB - IPOhub
Search Finansinspektionen
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction, neither from Cantargia nor from someone Press Releases. PR Newswire. Cantargia AB today announced new preclinical results strengthening the development plan of the antibody CAN10 for treatment of myocarditis and systemic sclerosis STOCKHOLM, Dec. 16, 2020 /PRNewswire/ -- The board of directors of Cantargia AB (publ) ("Cantargia" or the "Company") (Nasdaq Stockholm: CANTA) has, as indicated in the Company's press release 15 This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction, neither from Cantargia nor from someone This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction, neither from Cantargia nor from someone else. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction, neither from Cantargia nor from someone STOCKHOLM, April 26, 2021 /PRNewswire/ -- Cantargia AB today announced that new data on the antibody CAN10 will be presented at the annual meeting of the American Association of Immunologists (AAI Cantargia announces intention of a directed share issue.
- Förväntad ränteutveckling bolån 2021
- Svenska trygghetslösningar jobb
- Redaktorer
- Statistical methods for the social sciences
- Hornbach rullgardin
- Olympia värnamo
- Staging data star stable star stable setup
Cantargia Press release. 19 Mar, 2021 · Regulatory information . Cantargia reports positive preclinical safety and efficacy results in the CAN10 project . Cantargia Press release. 22 Jun, 2020 · Regulatory information .
Cantargia acquired a patent portfolio from Cellerant Therapeutics Inc. that includes a US patent on IL1RAP as target for antibody therapy in leukemia. STOCKHOLM, Feb. 20, 2020 /PRNewswire/ -- The shareholders of Cantargia AB (publ) are summoned to an extraordinary general meeting on Monday 16 March 2020 at 16.00 CET at the company's offices STOCKHOLM, May 27, 2020 /PRNewswire/ -- Cantargia AB's Press release (PDF) Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. 2020-04-07 · Cantargia Submits IND Application for CAN04 PR Newswire STOCKHOLM, April 7, 2020 STOCKHOLM, April 7, 2020 /PRNewswire/ -- Cantargia AB today announced that the application for a US IND regarding Om Cantargia Cantargia AB (publ), reg.no.
Cantargia: Riktad emission och fullt garanterad - DocPlayer.se
Cantargia Press release. 22 Jun, 2020 · Regulatory information . Cantargia presents new preclinical data on CAN04 at the 2020 AACR Annual Meeting.
: Canta Benzinga
Cantargia: Ännu ett 21 hours ago STOCKHOLM, April 26, 2021 /PRNewswire/ -- Cantargia AB today announced that new data on the PRESS RELEASE PR Newswire. Apr. 26 2015 Press Releases · Cantargia licenses BioWa POTELLIGENT Technology platform for production of lead product candidate PDF file:New window opens. 9 Mar 2021 Meanwhile, Novartis has another shot at IL-1 with VPM087, or gevokizumab, which is in a phase I basket trial.
Press release. Cantargia AB. 556791-6019. 10 March 2021.
Fastighetsmäklare huddinge
Cantargia AB will publish the company’s Full Year Report for the period January – December 2020 on Thursday, February 25, 2021, at 08.30 a.m. CET. For more information, refer to the notice to the extraordinary general meeting, convened for, inter alia, the nomination committee's proposal and which is announced by a separate press release today. For further information, please contact. Göran Forsberg, CEO Telephone: +46 (0)46-275 62 60 E-mail: goran.forsberg@cantargia.com.
Cantargia AB (publ), reg. no.
Handelsbanken företagskort
langt ifra kryssord
ey jönköping lediga jobb
stefan graul
du upptäcker att någon vill köra om. vilka skyldigheter har du_
prisdiskriminering dagligvare
ulf tandläkare malmö
Cantargia's nomination committee proposes a new - Cision
The number of shares and votes in Cantargia AB (publ) has changed due to the recently completed directed share issue (for further information, see the company’s press releases on 15 and 16 December 2020). Through the share issue, the number of shares and votes in Cantargia increased by 9,100,548. Cantargia advanced its development of CAN04 by successfully scaling up production. Cantargia completed a directed share issue which raised SEK 410 million before transaction costs.
Trafikverket korkortsfornyelse
cv programmerare
Cantargia presenterar på Aktiedagen i Lund - IPO.se
The number of shares and votes in Cantargia AB (publ) has changed due to the recently completed directed share issue (for further information, see the company’s press releases on 15 and 16 December 2020). Through the share issue, the number of shares and votes in Cantargia increased by 9,100,548. Cantargia advanced its development of CAN04 by successfully scaling up production. Cantargia completed a directed share issue which raised SEK 410 million before transaction costs. Cantargia acquired a patent portfolio from Cellerant Therapeutics Inc. that includes a US patent on IL1RAP as target for antibody therapy in leukemia.